TSC2 Gene Loss Disrupts Brain Development by Blocking Key Protein Production

This groundbreaking study reveals why patients with tuberous sclerosis complex (TSC) often develop autism and epilepsy, potentially opening new treatment avenues for these challenging conditions. TSC is caused by mutations in TSC1 or TSC2 genes, leading to overactive mTOR signaling and various symptoms including brain tumors and neurodevelopmental problems.

Researchers used CRISPR technology to create neural progenitor cells from a TSC2 patient, then studied how TSC2 loss affects early brain development. They employed advanced polysome profiling to examine protein production across thousands of genes simultaneously.

The key discovery was that TSC2 loss dramatically suppresses translation of genes associated with autism spectrum disorder, epilepsy, and other neurodevelopmental conditions. This explains the molecular basis for why TSC patients frequently develop these neurological symptoms. Current treatments like rapamycin target mTOR but fail to address neurodevelopmental issues.

Remarkably, two experimental drugs showed promise: RMC-6272 (a specific mTOR inhibitor) and eFT-508 (targeting MNK1/2 proteins) both restored normal protein production from affected genes and rescued developmental defects in laboratory models. Unlike rapamycin, RMC-6272 successfully reversed the cellular abnormalities.

These findings suggest that targeting specific protein synthesis pathways could treat the neurodevelopmental aspects of TSC, autism, and epilepsy - conditions that currently lack effective therapies. The research provides a molecular roadmap for developing treatments that address the root cause rather than just symptoms.